{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:08:03Z","timestamp":1794438483261,"version":"4.9.1"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K17467"],"award-info":[{"award-number":["20K17467"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.pharmthera.2023.108433","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T11:32:06Z","timestamp":1683199926000},"page":"108433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Bayesian prediction-based individualized dosing of anti-methicillin-resistant Staphylococcus aureus treatment: Recent advancements and prospects in therapeutic drug monitoring"],"prefix":"10.1016","volume":"246","author":[{"given":"Kazutaka","family":"Oda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Jono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2023.108433_bb0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0928-0987(97)10015-X","article-title":"Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to children","volume":"6","author":"Aarons","year":"1998","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/phar.2722","article-title":"Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis","volume":"42","author":"Abdelmessih","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0015","article-title":"Comparative in vivo efficacies of tedizolid in neutropenic versus immunocompetent murine streptococcus pneumoniae lung infection models","volume":"61","author":"Abdelraouf","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.624639","article-title":"Model-informed precision dosing of antibiotics in pediatric patients: a narrative review","volume":"9","author":"Abdulla","year":"2021","journal-title":"Frontiers in Pediatrics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0025","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/AAC.45.2.454-459.2001","volume":"45","author":"Akins","year":"2001","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0030","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40262-020-00866-2","article-title":"An update on population pharmacokinetic analyses of vancomycin part I: In Adults","volume":"59","author":"Aljutayli","year":"2020","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40262-021-01050-w","article-title":"An update on population pharmacokinetic analyses of vancomycin part II: in pediatric patients","volume":"61","author":"Aljutayli","year":"2022","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0045","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.50.4.1376-1383.2006","article-title":"Pharmacodynamics of a new cephalosporin PPI-0903 (TAK-599) active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0050","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","article-title":"In vivo pharmacodynamics of a new oxazolidinone (linezolid)","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40262-020-00945-4","article-title":"Population pharmacokinetics of unbound and total teicoplanin in critically ill pediatric patients","volume":"60","author":"Aulin","year":"2021","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0060","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jac\/dku368","article-title":"Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients","volume":"70","author":"Baietto","year":"2015","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0065","first-page":"376","article-title":"Vancomycin ototoxicity and nephrotoxicity. A review","volume":"3","author":"Bailie","year":"1988","journal-title":"Medical Toxicology and Adverse Drug Experience"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0070","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3390\/antibiotics11070914","article-title":"Daptomycin population pharmacokinetics in patients affected by severe gram-positive infections: an update","volume":"11","author":"Balice","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0075","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40262-022-01125-2","article-title":"A review of population pharmacokinetic analyses of linezolid","volume":"61","author":"Band\u00edn-Vilar","year":"2022","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0080","first-page":"181","article-title":"Linezolid Pharmacia Corp","volume":"1","author":"Barrett","year":"2000","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9343(02)01476-6","article-title":"Pharmacokinetic dosing of aminoglycosides: a controlled trial","volume":"114","author":"Bartal","year":"2003","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0090","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0095","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/AAC.02967-15","article-title":"Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations","volume":"60","author":"Bhavnani","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl. 4","key":"10.1016\/j.pharmthera.2023.108433_bb0100","first-page":"9","article-title":"Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity","volume":"65","author":"Biek","year":"2010","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0110","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dky541","article-title":"Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection","volume":"74","author":"Bricca","year":"2019","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0115","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.02000-12","article-title":"Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis","volume":"57","author":"Butterfield","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0120","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.cmi.2017.02.032","article-title":"Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic\/pharmacodynamic targets in adult patients with haematological malignancy","volume":"23","author":"Byrne","year":"2017","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0125","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkx473","article-title":"Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy","volume":"73","author":"Byrne","year":"2018","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0130","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1128\/AAC.34.12.2348","article-title":"Comparative efficacy of daptomycin vancomycin and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination","volume":"34","author":"Cantoni","year":"1990","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis","volume":"9","author":"Carrothers","year":"2020","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0145","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1093\/jac\/dkx242","article-title":"Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen","volume":"72","author":"Cazaubon","year":"2017","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0150","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1093\/jac\/dkac299","article-title":"Population pharmacokinetic\/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance","volume":"77","author":"Chauzy","year":"2022","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0155","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02535-16","article-title":"Establishment of an AUC0-24 threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus Bacteremia","volume":"61","author":"Chavada","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0160","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jac\/dkt342","article-title":"Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment","volume":"69","author":"Chaves","year":"2014","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0165","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/jac\/dkx140","article-title":"Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies","volume":"72","author":"Cojutti","year":"2017","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0170","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/jac\/dkz374","article-title":"Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study","volume":"74","author":"Cojutti","year":"2019","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0175","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02260-20","article-title":"Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections","volume":"65","author":"Cojutti","year":"2021","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106445","article-title":"Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept","volume":"58","author":"Cojutti","year":"2021","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0185","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/antibiotics11080996","article-title":"Population pharmacokinetic and pharmacodynamic analysis of dalbavancin for long-term treatment of subacute and\/or chronic infectious diseases: the major role of therapeutic drug monitoring","volume":"11","author":"Cojutti","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0190","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40262-018-0727-5","article-title":"Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations","volume":"58","author":"Colin","year":"2019","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infectious Disease Clinics of North America"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0200","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1128\/AAC.01273-07","article-title":"In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models","volume":"52","author":"Craig","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0205","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jcpt.13359","article-title":"Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients","volume":"46","author":"Dai","year":"2021","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0210","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/BF01070904","article-title":"Optimal sampling times for pharmacokinetic experiments","volume":"9","author":"D\u2019Argenio","year":"1981","journal-title":"Journal of Pharmacokinetics and Biopharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0215","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0220","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","article-title":"Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy","volume":"61","author":"Darwich","year":"2021","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0225","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijantimicag.2013.06.006","article-title":"Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections","volume":"42","author":"Di Paolo","year":"2013","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0230","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","article-title":"Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients","volume":"33","author":"Dong","year":"2014","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijid.2020.03.054","article-title":"Dosage regimen and toxicity risk assessment of linezolid in sepsis patients","volume":"96","author":"Dou","year":"2020","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0240","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/0091270008321273","article-title":"Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic","volume":"48","author":"Dowell","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0245","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1001\/archinte.1989.00390080053013","article-title":"Mild nephrotoxicity associated with vancomycin use","volume":"149","author":"Downs","year":"1989","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0250","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/FTD.0000000000000900","article-title":"Bayesian forecasting for intravenous tobramycin dosing in adults with cystic fibrosis using one versus two serum concentrations in a dosing interval","volume":"43","author":"Drennan","year":"2021","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0255","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/j.1875-9114.1998.tb03109.x","article-title":"The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials","volume":"18","author":"Dresser","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0260","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0265","first-page":"93","article-title":"Good practices in model-informed drug discovery and development: practice, application, and documentation","volume":"5","author":"EFPIA MID3 Workgroup","year":"2016","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0270","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1469-0691.2006.01455.x","article-title":"EUCAST technical note on daptomycin","volume":"12","author":"EUCAST","year":"2006","journal-title":"Clinical Microbiology and Infection"},{"issue":"Spec Feature","key":"10.1016\/j.pharmthera.2023.108433_bb0275","first-page":"111","article-title":"Sivextro (tedizolid phosphate) approved for the treatment of adults with acute bacterial skin and skin-structure infections","volume":"8","author":"Fala","year":"2015","journal-title":"American Health & Drug Benefits"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0280","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0285","doi-asserted-by":"crossref","first-page":"493","DOI":"10.21037\/atm.2020.03.207","article-title":"Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?-Experience from a prospective observational study","volume":"8","author":"Fang","year":"2020","journal-title":"The Annals of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0290","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0295","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1128\/AAC.03423-14","article-title":"Tedizolid population pharmacokinetics, exposure response, and target attainment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0300","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/j.1875-9114.1992.tb04516.x","article-title":"Teicoplanin nephrotoxicity: first case report","volume":"12","author":"Frye","year":"1992","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0305","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fphar.2020.00552","article-title":"Population pharmacokinetics and dosage optimization of teicoplanin in children with different renal functions","volume":"11","author":"Gao","year":"2020","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0310","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.3390\/pharmaceutics14102226","article-title":"Population pharmacokinetic\/pharmacodynamic modelling of daptomycin for schedule optimization in patients with renal impairment","volume":"14","author":"Garc\u00eda-Mart\u00ednez","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0315","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/jac\/dkab006","article-title":"Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference","volume":"76","author":"Garreau","year":"2021","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0320","first-page":"564","article-title":"Some laboratory and clinical experiences with a new antibiotic, vancomycin","volume":"31","author":"Geraci","year":"1956","journal-title":"Proceedings of the Staff Meetings. Mayo Clinic"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0325","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/INF.0000000000001538","article-title":"Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age","volume":"36","author":"Gonzalez","year":"2017","journal-title":"The Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0330","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1128\/AAC.02597-15","article-title":"Pharmacokinetic variability of daptomycin during prolonged therapy for bone and joint infections","volume":"60","author":"Goutelle","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0335","first-page":"117","article-title":"Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment","volume":"74","author":"Gr\u00e9goire","year":"2019","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0340","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/dkab499","article-title":"Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese society of chemotherapy and the Japanese Society of therapeutic drug monitoring","volume":"77","author":"Hanai","year":"2022","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"issue":"Suppl. 5","key":"10.1016\/j.pharmthera.2023.108433_bb0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/1120009X.2000.11782313","article-title":"Comparative pharmacokinetics of teicoplanin and vancomycin","volume":"12","author":"Harding","year":"2000","journal-title":"Journal of Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0350","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/pharmaceutics14010114","article-title":"Implementation and comparison of two pharmacometric tools for model-based therapeutic drug monitoring and precision dosing of daptomycin","volume":"14","author":"Heitzmann","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0355","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00365548.2011.608712","article-title":"Correlation between serum linezolid concentration and the development of thrombocytopenia","volume":"44","author":"Hiraki","year":"2012","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0360","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0365","first-page":"1150","article-title":"A hybrid machine learning\/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors","volume":"10","author":"Hughes","year":"2021","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0370","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jac\/dkg160","article-title":"In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods","volume":"51","author":"Jacqueline","year":"2003","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0375","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.cmi.2022.03.041","article-title":"Precision dosing software to optimize antimicrobial dosing: a systematic search and follow-up survey of available programs","volume":"28","author":"Jager","year":"2022","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0380","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","article-title":"Precision medicine--personalized, problematic, and promising","volume":"372","author":"Jameson","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0385","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00003088-199834010-00003","article-title":"Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new \u201cmultiple model\u201d dosage design, bayesian feedback and individualised target goals","volume":"34","author":"Jelliffe","year":"1998","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0390","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jiac.2017.12.002","article-title":"Population pharmacokinetics of teicoplanin in hospitalized elderly patients using cystatin C as an indicator of renal function","volume":"24","author":"Kasai","year":"2018","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0395","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.csbj.2016.12.005","article-title":"Machine learning and data mining methods in diabetes research","volume":"15","author":"Kavakiotis","year":"2017","journal-title":"Computational and Structural Biotechnology Journal"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0400","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01914-19","article-title":"Pharmacokinetics of telavancin in adult patients with cystic fibrosis during acute pulmonary exacerbation","volume":"64","author":"Kidd","year":"2019","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0405","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/1120009X.2022.2043538","article-title":"Initial trough concentration may be beneficial in preventing linezolid-induced thrombocytopenia","volume":"34","author":"Komatsu","year":"2022","journal-title":"Journal of Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0410","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01971-19","article-title":"Population pharmacokinetics of teicoplanin in preterm and term neonates: is it time for a new dosing regimen?","volume":"64","author":"Kontou","year":"2020","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0415","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/ajhp\/zxz070","article-title":"Readiness to implement vancomycin monitoring based on area under the concentration-time curve: A cross-sectional survey of a national health consortium","volume":"76","author":"Kufel","year":"2019","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0420","first-page":"1511","article-title":"Antibacterial activity and ototoxicity in guinea pigs, and nephrotoxicity in rats of arbekacin","volume":"36","author":"Kurebe","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0425","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-200443040-00004","article-title":"Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients","volume":"43","author":"Le Guellec","year":"2004","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0430","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/AAC.01717-15","article-title":"Impact of glycopeptide resistance in Staphylococcus aureus on the Dalbavancin in vivo pharmacodynamic target","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0435","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00895-21","article-title":"Population pharmacokinetics, exposure-response, and probability of target attainment analyses for tedizolid in adolescent patients with acute bacterial skin and skin structure infections","volume":"65","author":"Li","year":"2021","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0440","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/AAC.49.2.770-772.2005","article-title":"Antistaphylococcal activity of dalbavancin, an experimental glycopeptide","volume":"49","author":"Lin","year":"2005","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0445","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0450","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/cid\/ciaa1744","article-title":"Vancomycin area under the curve-guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant Staphylococcus aureus infections: putting the safety of our patients first","volume":"72","author":"Lodise","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0455","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1128\/AAC.01110-07","article-title":"Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0460","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/AAC.00383-11","article-title":"Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function","volume":"56","author":"Lodise","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0465","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1128\/AAC.40.5.1242","article-title":"Population pharmacokinetic study of teicoplanin in severely neutropenic patients","volume":"40","author":"Lortholary","year":"1996","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105818","article-title":"Population pharmacokinetics and individual analysis of daptomycin in kidney transplant recipients","volume":"162","author":"Lou","year":"2021","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0475","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0480","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1128\/AAC.01565-10","article-title":"In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model","volume":"55","author":"Louie","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0485","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02490-20","article-title":"Dosage individualization of linezolid: precision dosing of linezolid to optimize efficacy and minimize toxicity","volume":"65","author":"Luque","year":"2021","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0490","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1128\/AAC.00933-10","article-title":"Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection","volume":"55","author":"MacGowan","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0495","first-page":"241","article-title":"Reinforcement learning and Bayesian data assimilation for model-informed precision dosing in oncology","volume":"10","author":"Maier","year":"2021","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0500","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.7164\/antibiotics.39.1430","article-title":"Teicoplanin, antibiotics from Actinoplanes teichomyceticus nov. sp. VII. Preparation and NMR characteristics of the aglycone of teicoplanin","volume":"39","author":"Malabarba","year":"1986","journal-title":"Journal of Antibiotics (Tokyo)"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","article-title":"Vancomycin: a review of population pharmacokinetic analyses","volume":"51","author":"Marsot","year":"2012","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0510","first-page":"139","article-title":"Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens","volume":"6","author":"Matsumoto","year":"2014","journal-title":"Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0515","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.02.019","article-title":"Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction","volume":"36","author":"Matsumoto","year":"2010","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0520","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0525","first-page":"15","article-title":"Pharmacokinetic\/pharmacodynamic analysis of teicoplanin in patients with MRSA infections","volume":"8","author":"Matsumoto","year":"2016","journal-title":"Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0530","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1248\/bpb.b22-00276","article-title":"Target therapeutic ranges of anti-MRSA drugs, linezolid, tedizolid and daptomycin, and the necessity of TDM","volume":"45","author":"Matsumoto","year":"2022","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0535","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical Practice Guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0540","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/AAC.47.2.548-553.2003","article-title":"Population pharmacokinetics of linezolid in patients treated in a compassionate-use program","volume":"47","author":"Meagher","year":"2003","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2023.108433_bb0545","first-page":"25","article-title":"Ceftobiprole medocaril","volume":"35","author":"M\u00e9ndez","year":"2022","journal-title":"Revista Espa\u00f1ola de Quimioterapia"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0550","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","article-title":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - results of a randomised, multicentre phase 3 study","volume":"24","author":"Mikamo","year":"2018","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0555","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0560","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cpt.334","article-title":"Clinical decision support tools: the evolution of a revolution","volume":"99","author":"Mould","year":"2016","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0565","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0570","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FTD.0000000000000276","article-title":"Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software","volume":"38","author":"Neely","year":"2016","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0575","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0580","first-page":"165","article-title":"Development of new software (Ver. 2.0) based on the Bayesian estimation utilized in the therapeutic drug monitoring of teicoplanin a glycopeptide antibiotic","volume":"59","author":"Niwa","year":"2006","journal-title":"The Japanese Journal of Antibiotics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0585","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijantimicag.2009.12.018","article-title":"Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics","volume":"35","author":"Niwa","year":"2010","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0590","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0595","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/FTD.0000000000000002","article-title":"Therapeutic drug monitoring based on early measurements of serum teicoplanin levels in Japanese patients","volume":"36","author":"Oda","year":"2014","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0600","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jiac.2019.11.009","article-title":"Development and evaluation of a vancomycin dosing nomogram to achieve the target area under the concentration-time curve. A retrospective study","volume":"26","author":"Oda","year":"2020","journal-title":"Journal of Infection and Chemotherapy"},{"issue":"37","key":"10.1016\/j.pharmthera.2023.108433_bb0605","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11095-020-02820-0","article-title":"Development of vancomycin dose individualization strategy by Bayesian prediction in patients receiving continuous renal replacement therapy","author":"Oda","year":"2020","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106109","article-title":"Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15-20 \u03bcg\/mL concentration","volume":"56","author":"Oda","year":"2020","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0615","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11095-021-03030-y","article-title":"Performance of area under the concentration-time curve estimations of vancomycin with limited sampling by a newly developed web application","volume":"38","author":"Oda","year":"2021","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0620","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jiac.2020.08.002","article-title":"Evaluation of once-daily dosing and target concentrations in therapeutic drug monitoring for arbekacin: a meta-analysis","volume":"27","author":"Oda","year":"2021","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0625","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cpdd.684","article-title":"Population pharmacokinetics and pharmacodynamics of teicoplanin and C-reactive protein in hospitalized patients with gram-positive infections","volume":"9","author":"Ogami","year":"2020","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0630","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/FTD.0000000000000816","article-title":"External evaluation of population pharmacokinetics and pharmacodynamics in linezolid-induced thrombocytopenia: the transferability of published models to different hospitalized patients","volume":"43","author":"Ogami","year":"2021","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0635","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5414\/CP201739","article-title":"Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection","volume":"51","author":"Ogawa","year":"2013","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0640","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bjid.2015.12.007","article-title":"Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections","volume":"20","author":"Ortiz-Covarrubias","year":"2016","journal-title":"The Brazilian Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0645","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1128\/AAC.34.11.2114","article-title":"Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses","volume":"34","author":"Outman","year":"1990","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0650","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jiac.2020.06.006","article-title":"Teicoplanin and therapeutic drug monitoring: an update for optimal use in different patient populations","volume":"26","author":"Pea","year":"2020","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0655","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0660","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-year experience of Therapeutic Drug Monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0665","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd.2015.22","article-title":"The right dose for every patient: a key step for precision medicine","volume":"15","author":"Peck","year":"2016","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0670","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.3390\/pharmaceutics14122731","article-title":"Model-Informed Precision Dosing (MIPD)","volume":"14","author":"P\u00e9rez-Blanco","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0675","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/17512433.2018.1501271","article-title":"Precision dosing in clinical medicine: present and future","volume":"11","author":"Polasek","year":"2018","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0680","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1208\/s12248-018-0286-6","article-title":"What does it take to make model-informed precision dosing common practice? Report from the 1st Asian Symposium on precision dosing","volume":"21","author":"Polasek","year":"2019","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0690","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1128\/AAC.03685-14","article-title":"Population pharmacokinetics of teicoplanin in children","volume":"58","author":"Ramos-Mart\u00edn","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0695","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1093\/jac\/dkw295","article-title":"Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy","volume":"71","author":"Ramos-Mart\u00edn","year":"2016","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0700","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/jac\/dkx289","article-title":"Pharmacodynamics of teicoplanin against MRSA","volume":"72","author":"Ramos-Mart\u00edn","year":"2017","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0705","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00707-17","article-title":"Tools for the individualized therapy of teicoplanin for neonates and children","volume":"61","author":"Ramos-Mart\u00edn","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0710","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","article-title":"Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics","volume":"42","author":"Rao","year":"2020","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0715","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0720","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/FTD.0000000000000196","article-title":"Therapeutic drug monitoring of daptomycin: a retrospective monocentric analysis","volume":"37","author":"Reiber","year":"2015","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0725","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/jac\/25.4.679","article-title":"Nephrotoxicity of vancomycin, alone and with an aminoglycoside","volume":"25","author":"Rybak","year":"1990","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0730","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0735","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0740","article-title":"Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020)","volume":"105","author":"Sader","year":"2022","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0745","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0750","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/FTD.0000000000000906","article-title":"Population pharmacokinetics of teicoplanin and its dosing recommendations for neutropenic patients with augmented renal clearance for hematological malignancies","volume":"43","author":"Sako","year":"2021","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0755","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/phar.2719","article-title":"Population pharmacokinetics of linezolid and its major metabolites PNU-142300 and PNU-142586 in adult patients","volume":"42","author":"Sakurai","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0760","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/AAC.05915-11","article-title":"Population pharmacokinetics of telavancin in healthy subjects and patients with infections","volume":"56","author":"Samara","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0765","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s11095-021-03058-0","article-title":"Population pharmacokinetic analysis and dosing optimization based on unbound daptomycin concentration and Cystatin C in nonobese elderly patients with hypoalbuminemia and chronic kidney disease","volume":"38","author":"Samura","year":"2021","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0770","first-page":"1056","article-title":"Study on an auto-simulation apparatus for evaluating bactericidal activity of antibiotics in human serum","volume":"41","author":"Sasaki","year":"1993","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0775","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/AAC.00480-05","article-title":"Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus","volume":"50","author":"Sato","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0780","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01086153","article-title":"Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients","volume":"4","author":"Sawchuk","year":"1976","journal-title":"Journal of Pharmacokinetics and Biopharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0785","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0790","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cpt1979263294","article-title":"Forecasting individual pharmacokinetics","volume":"26","author":"Sheiner","year":"1979","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0795","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bcp.14965","article-title":"Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: a systematic review and meta-analysis","volume":"88","author":"Shi","year":"2022","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0800","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1093\/jac\/dkaa320","article-title":"Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure","volume":"75","author":"Shingde","year":"2020","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0805","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijantimicag.2018.03.008","article-title":"Population pharmacokinetics of daptomycin in critically ill patients","volume":"52","author":"Soraluce","year":"2018","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0810","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00027-20","article-title":"Accumulation of major linezolid metabolites in patients with renal impairment","volume":"64","author":"Souza","year":"2020","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0815","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/01.ftd.0000249942.14145.ff","article-title":"Teicoplanin population pharmacokinetic analysis in hospitalized patients","volume":"28","author":"Soy","year":"2006","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0820","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40268-015-0117-5","article-title":"Applicability of a single time point strategy for the prediction of area under the concentration curve of linezolid in patients: superiority of ctrough- over cmax-derived linear regression models","volume":"16","author":"Srinivas","year":"2016","journal-title":"Drugs in R&D"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0825","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0830","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/AAC.42.12.3251","article-title":"The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria","volume":"42","author":"Swaney","year":"1998","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0835","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF02353410","article-title":"Predictive performance of the Bayesian analysis: effects of blood sampling time, population parameters, and pharmacostatistical model","volume":"22","author":"Tanigawara","year":"1994","journal-title":"Journal of Pharmacokinetics and Biopharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0840","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1111\/bcp.14360","article-title":"Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients","volume":"86","author":"Ter Heine","year":"2020","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0845","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s13104-016-2252-7","article-title":"The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis","volume":"9","author":"Tongsai","year":"2016","journal-title":"BMC Research Notes"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0850","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0855","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0860","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/phar.2191","article-title":"Review and validation of Bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients","volume":"38","author":"Turner","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0865","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1093\/jac\/dkac131","article-title":"Determination of plasma protein binding of dalbavancin","volume":"77","author":"Turner","year":"2022","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0870","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00210-019-01647-w","article-title":"A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure","volume":"392","author":"Ullah","year":"2019","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0875","first-page":"711","article-title":"Optimized sampling to estimate vancomycin drug exposure: Comparison of pharmacometric and equation-based approaches in a simulation-estimation study","volume":"11","author":"Uster","year":"2022","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0880","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cpt.2065","article-title":"A model averaging\/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study","volume":"109","author":"Uster","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0885","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/jac\/33.4.811","article-title":"A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient","volume":"33","author":"Vance-Bryan","year":"1994","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0890","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000189175","article-title":"Teicoplanin-induced thrombocytopenia","volume":"73","author":"Veldman","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0895","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1128\/AAC.13.1.30","article-title":"Sensitive bioassay for vancomycin","volume":"13","author":"Walker","year":"1978","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0900","article-title":"A novel UPLC-MS\/MS assay for the measurement of linezolid and its metabolite PNU-142300 in human serum and its application to patients with renal insufficiency","volume":"12","author":"Wang","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0905","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jgar.2020.11.014","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model","volume":"24","author":"Watanabe","year":"2021","journal-title":"The Journal of Global Antimicrobial Resistance"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0910","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01015-17","article-title":"Population pharmacokinetics and dose optimization of teicoplanin during venoarterial extracorporeal membrane oxygenation","volume":"61","author":"Wi","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0915","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijantimicag.2014.12.010","article-title":"TDMx: a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine","volume":"45","author":"Wicha","year":"2015","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0920","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0925","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"39","author":"Wilson","year":"2000","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0930","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/jac\/dkaa028","article-title":"Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy","volume":"75","author":"Xie","year":"2020","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0935","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bcp.13131","article-title":"Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy","volume":"83","author":"Xu","year":"2017","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0940","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jiac.2019.11.002","article-title":"Observational study to determine the optimal dose of daptomycin based on pharmacokinetic\/pharmacodynamic analysis","volume":"26","author":"Yamada","year":"2020","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0945","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/FTD.0000000000000930","article-title":"Optimal teicoplanin dosing regimen in neonates and children developed by leveraging real-world clinical information","volume":"44","author":"Yamada","year":"2022","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2022.100444","article-title":"Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis","volume":"44","author":"Yamada","year":"2022","journal-title":"Drug Metabolism and Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0955","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02353784","article-title":"Population pharmacokinetics of teicoplanin in patients with endocarditis","volume":"23","author":"Yu","year":"1995","journal-title":"Journal of Pharmacokinetics and Biopharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0960","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.594562","article-title":"Population pharmacokinetics and model-based dosing optimization of teicoplanin in pediatric patients","volume":"11","author":"Zhang","year":"2020","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0965","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00133-20","article-title":"Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction","volume":"64","author":"Zhang","year":"2020","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0970","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/bcp.12710","article-title":"Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease","volume":"80","author":"Zhao","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108433_bb0975","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jgar.2022.05.016","article-title":"External validation of vancomycin population pharmacokinetic models in ten cohorts of infected Chinese patients","volume":"30","author":"Zhou","year":"2022","journal-title":"The Journal of Global Antimicrobial Resistance"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:31:53Z","timestamp":1759012313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":193,"alternative-id":["S0163725823000979"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108433","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bayesian prediction-based individualized dosing of anti-methicillin-resistant Staphylococcus aureus treatment: Recent advancements and prospects in therapeutic drug monitoring","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108433"}}